Clear All
727 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
HCPCS Generic Name Brand Name Strength SEER*Rx Category Major Drug Class Minor Drug Class Oral (Y/N) FDA Approval Year FDA Discontinuation Year CMS Effective Date CMS Discontinuation Date Status
J9206 Irinotecan Camptosar 20 mg Chemotherapy Topoisomerase I Inhibitor Campothecin Analogs No 1996 Jan 1, 1998 In Use
NA Palbociclib Ibrance 75 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2015 In Use
J9324 Pemetrexed disodium Pemrydi-rtu 10mg Chemotherapy Antimetabolite Folic Acid Analog No 2023 Dec 7, 2023 In Use
NA Ruxolitinib Jakafi 20 mg Chemotherapy Enzyme Inhibitor JAK 1/2 Yes 2011 In Use
NA Abemaciclib Verzenio 200 mg Chemotherapy Cyclin Dependent Kinase Inhibitor CDK 4/6 Yes 2017 In Use
J8561 Everolimus Afinitor, Afinitor Disperz 0.25 mg Chemotherapy Enzyme Inhibitor mTOR Yes 2009 Jan 1, 2012 Dec 31, 2012 No Longer Used
J7527 Everolimus Afinitor, Afinitor Disperz 0.25 mg Chemotherapy Enzyme Inhibitor mTOR Yes 2009 Jan 1, 2013 In Use
S0156 Exemestane Aromasin 25 mg Hormonal Therapy Aromatase Inhibitor Yes 1999 Jan 1, 2001 In Use
J9358 Fam-trastuzumab deruxtecan-nxki Enhertu 1mg Immunotherapy Drug Antibody Conjugate HER2, topoisomerase, tetrapeptide No 2019 Jul 1, 2020 In Use
J1442 Filgrastim Neupogen, Zarxio 1 mcg Ancillary Therapy Immunostimulant Granulocyte Colony-Stimulating Factor No 1991 Jan 1, 2016 In Use
NA Trifluridine and Tipiracil Lonsurf 15/6.14 mg Chemotherapy Antimetabolite Pyrimidine Analog Yes 2015 In Use
NA Imiquimod Aldara 5% Immunotherapy Immunomodulator Retinoic Acid Derivative No 1997 In Use
C9273 Sipuleucel-T Provenge 1 dose = minimum of 50 million autologous cd54+ cells activated with pap-gm-csf Immunotherapy Immunomodulator Prostatic Acid Phosphatase No 2010 Oct 1, 2010 Jun 30, 2011 No Longer Used
NA Tivozanib Fotivda 0.89mg, 1.34mg Chemotherapy Tyrosine Kinase Inhibitor VEGFR Yes 2021 In Use
J9348 Naxitamab Danyelva 1mg Immunotherapy Monoclonal Antibody GD2 No 2020 Jul 23, 2021 In Use
J9113 Cemiplimab-rwlc Libtayo 1mg Immunotherapy Checkpoint Inhibitor PD-1 No 2018 Oct 1, 2019 In Use
NA Rucaparib Rubraca 250 mg Chemotherapy Enzyme Inhibitor PARP Yes 2017 In Use
Not yet assigned Tisagenlecleucel Kymriah consult labeling Immunotherapy CAR-T CD19 No 2017 In Use
NA Testolactone Teslac 250 mg Hormonal Therapy Androgen Yes 1970 Jun 25, 2005 No Longer Used
J3130 Testosterone Enanthate Testosterone Enanthate 200 mg Hormonal Therapy Androgen No 1953 Jan 1, 1982 Jan 1, 2015 No Longer Used
NA Ceritinib Zykadia 150 mg Chemotherapy Tyrosine Kinase Inhibitor ALK Yes 2014 In Use
NA Dasatinib Sprycel 100 mg Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Yes 2006 In Use
J9176 Elotuzumab Empliciti 1 mg Immunotherapy Monoclonal Antibody SLAMF7 No 2015 Jan 1, 2017 In Use
NA Fedratinib Hydrochloride Inrebic 100mg Chemotherapy Enzyme Inhibitor JAK2, FLT3 Yes 2019 In Use
J1323 Elranatamab-bcmm Elranatamab-bcmm 1mg Immunotherapy Monoclonal Antibody BCMA, CD3 No 2023 Apr 17, 2024 In Use
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is truly not available.